Literature DB >> 22184375

Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer.

Peter S Nelson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22184375     DOI： 10.1200/JCO.2011.39.1300

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  46 in total

1.  Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.

Authors:  C Coarfa; W Fiskus; V K Eedunuri; K Rajapakshe; C Foley; S A Chew; S S Shah; C Geng; J Shou; J S Mohamed; B W O'Malley; N Mitsiades
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

2.  Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.

Authors:  Emmanuel S Antonarakis; Scott T Tagawa; Giuseppe Galletti; Daniel Worroll; Karla Ballman; Marie Vanhuyse; Guru Sonpavde; Scott North; Costantine Albany; Che-Kai Tsao; John Stewart; Atef Zaher; Ted Szatrowski; Wei Zhou; Ada Gjyrezi; Shinsuke Tasaki; Luigi Portella; Yang Bai; Timothy B Lannin; Shalu Suri; Conor N Gruber; Erica D Pratt; Brian J Kirby; Mario A Eisenberger; David M Nanus; Fred Saad; Paraskevi Giannakakou
Journal:  J Clin Oncol       Date:  2017-06-20       Impact factor: 44.544

3.  A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer.

Authors:  Atish D Choudhury; Kathryn P Gray; Jeffrey G Supko; Lauren C Harshman; Mary-Ellen Taplin; Amanda F Pace; Matthew Farina; Katherine A Zukotynski; Brandon Bernard; Philip W Kantoff; Mark Pomerantz; Christopher Sweeney
Journal:  Prostate       Date:  2018-06-07       Impact factor: 4.104

Review 4.  Perspectives on treatment of metastatic castration-resistant prostate cancer.

Authors:  Axel S Merseburger; Joaquim Bellmunt; Cheryl Jenkins; Chris Parker; John M Fitzpatrick
Journal:  Oncologist       Date:  2013-05-13

5.  Targeted androgen pathway suppression in localized prostate cancer: a pilot study.

Authors:  Elahe A Mostaghel; Peter S Nelson; Paul Lange; Daniel W Lin; Mary Ellen Taplin; Steven Balk; William Ellis; Philip Kantoff; Brett Marck; Daniel Tamae; Alvin M Matsumoto; Lawrence D True; Robert Vessella; Trevor Penning; Rachel Hunter Merrill; Roman Gulati; Bruce Montgomery
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

6.  Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation.

Authors:  Chen-Lin Hsieh; Teng Fei; Yiwen Chen; Tiantian Li; Yanfei Gao; Xiaodong Wang; Tong Sun; Christopher J Sweeney; Gwo-Shu Mary Lee; Shaoyong Chen; Steven P Balk; Xiaole Shirley Liu; Myles Brown; Philip W Kantoff
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

7.  Androgen receptor splice variants determine taxane sensitivity in prostate cancer.

Authors:  Maria Thadani-Mulero; Luigi Portella; Shihua Sun; Matthew Sung; Alexandre Matov; Robert L Vessella; Eva Corey; David M Nanus; Stephen R Plymate; Paraskevi Giannakakou
Journal:  Cancer Res       Date:  2014-02-20       Impact factor: 12.701

8.  PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality.

Authors:  Eric G Bluemn; Elysia Sophie Spencer; Brigham Mecham; Ryan R Gordon; Ilsa Coleman; Daniel Lewinshtein; Elahe Mostaghel; Xiaotun Zhang; James Annis; Carla Grandori; Christopher Porter; Peter S Nelson
Journal:  Mol Cancer Res       Date:  2013-03-14       Impact factor: 5.852

9.  Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.

Authors:  Michael D Nyquist; Alexandra Corella; Ilsa Coleman; Navonil De Sarkar; Arja Kaipainen; Gavin Ha; Roman Gulati; Lisa Ang; Payel Chatterjee; Jared Lucas; Colin Pritchard; Gail Risbridger; John Isaacs; Bruce Montgomery; Colm Morrissey; Eva Corey; Peter S Nelson
Journal:  Cell Rep       Date:  2020-05-26       Impact factor: 9.423

10.  Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential.

Authors:  Giuseppe Galletti; Luigi Portella; Scott T Tagawa; Brian J Kirby; Paraskevi Giannakakou; David M Nanus
Journal:  Mol Diagn Ther       Date:  2014-08       Impact factor: 4.074
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.